Singapore markets close in 57 minutes
Straits Times Index
3,267.46 +42.29 (+1.31%) Nikkei
37,552.16 +113.55 (+0.30%) Hang Seng
16,812.94 +301.25 (+1.82%) FTSE 100
8,061.38 +37.51 (+0.47%) Bitcoin USD
66,129.31 +85.69 (+0.13%) CMC Crypto 200
1,393.97 -20.79 (-1.47%)
Mirum Pharmaceuticals, Inc. (MIRM)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 23.81 |
| Open | 23.97 |
| Bid | 24.12 x 200 |
| Ask | 24.26 x 100 |
| Day's range | 23.75 - 24.51 |
| 52-week range | 23.29 - 35.56 |
| Volume | |
| Avg. volume | 500,161 |
| Market cap | 1.136B |
| Beta (5Y monthly) | 1.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.00 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 48.91 |
Business WireMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., April 11, 2024--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business WireMirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
FOSTER CITY, Calif., April 02, 2024--Mirum's LIVMARLI Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
ZacksMirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
© 2024 Yahoo. All rights reserved.